Would switching agents help the shedding, or is the rate of loss the only variable that matters?

Second wave of shedding, nine months in, and I have been told by two people in strong terms that switching from tirzepatide to semaglutide will fix it because tirzepatide is "harder on hair". I cannot find anything resembling evidence for that claim and it does not sound like it could be true, but I do not know enough to dismiss it.

My working assumption is that if the mechanism is telogen effluvium from rapid loss, then the agent is irrelevant except insofar as it determines how fast I lose weight, and the same rate on a different drug would produce the same result. Is that right? And if it is, what is the actual quantitative relationship — is there a rate of loss below which this stops happening?

Losing about 1.1 kg/week currently, which I suspect is the answer to my own question.

Your working assumption is right and the claim you were given is not supported. Switching agents changes the shedding only through its effect on your rate of loss and your intake. If a switch slows you down, it will help; if you reach the same rate on the new agent, it will not. And yes, 1.1 kg/week nine months in is almost certainly the answer.

Why the agent is not the variable

Three arguments, in descending order of strength:

1. The bariatric surgery literature. Telogen effluvium at reported frequencies of roughly 40-70% in the first post-operative year, peaking at three to four months. No GLP-1 agonist involved. If a single non-pharmacological intervention that produces rapid loss and reduced intake generates the same syndrome with the same timing at higher frequency than any drug in this class, the drug is not the mechanism.
2. The gradient across agents tracks weight loss rather than receptor profile. Reported alopecia rates order roughly as semaglutide < tirzepatide < the higher-dose multi-agonists, which is also the ordering of mean weight loss. Those agents have substantially different receptor profiles — GLP-1 alone, GLP-1 plus GIP, and combinations adding glucagon — and there is no coherent story in which that ordering of receptor targets predicts follicle effects while coincidentally matching the ordering of weight loss.
3. No mechanism has been established. GLP-1 receptor expression in the hair follicle is not a described feature of follicle biology in the way that androgen receptor expression is. Absence of a mechanism is weak evidence on its own, but combined with the two points above it matters.

What is true, and probably the origin of the claim: tirzepatide produces more weight loss on average than semaglutide, so in any given population more tirzepatide users will be losing fast enough to shed. That is a real observation with a wrong explanation attached.

Is there a rate below which this stops?

No sharp threshold exists in the literature, and anyone quoting one precisely is overstating the evidence. What can be said is more useful than nothing:

Note that the useful unit is percentage of body weight per week, not kilograms. 1.1 kg/week means very different things at 140 kg and at 75 kg. Work yours out: at 90 kg, 1.1 kg is 1.22% per week, which is in the top band. At 130 kg it is 0.85%, which is intermediate. That single calculation is more informative than the raw figure and it is the first thing I would do with your number.

The implied energy deficit is also worth computing, because it is the physiological quantity. At roughly 7,700 kcal per kilogram of tissue, 1.1 kg/week is 1.1 × 7,700 / 7 ≈ 1,210 kcal/day of deficit. That is a very large sustained deficit, larger than most structured weight-loss programmes would prescribe, and it is quite sufficient to produce a second effluvium wave on its own.

What actually to change

1. Slow the rate. The lever is intake, and paradoxically the way to slow loss on this class is usually to eat more rather than to reduce the dose, because it is intake rather than the drug that sets the deficit. Eating more protein specifically addresses two problems at once.
2. Protein to target, measured. 1.2-1.6 g/kg is the usual range cited for a substantial deficit, and hitting it at low total intake requires deliberate planning rather than good intentions.
3. Test iron, thyroid, B12 and zinc if you have not. A second wave nine months in raises the possibility of a chronic effluvium with a nutritional driver rather than a single acute event.
4. Do not switch agents for this reason. There are legitimate reasons to switch — tolerability, response, cost, supply — and hair is not one of them on current evidence. Switching also resets your titration, which means a period of worse GI symptoms and probably worse intake, which is the opposite of what you want here.

One thing worth adding about expectations. A second wave at nine months, having had a first wave, is characteristic of continued rapid loss rather than of anything new going wrong. It also means you are further into a process that resolves. If you slow the rate and fix intake now, the insult stops, and the shedding stops two to four months later — not immediately, because of the telogen lag. Expecting an immediate response to an intervention is the most common reason people conclude an intervention failed here.

edited 25 Oct 2025 by harriet_lonsdale — removed a claim I could not source

Worth separating out the possibility that gets missed when everything is attributed to effluvium: that some of what people see is androgenetic alopecia becoming visible, which is a different condition with a different natural history and different treatments.

Telogen effluvium reduces overall density temporarily and uniformly. In someone with pre-existing pattern hair loss, that has a specific consequence: the areas already thinning were being camouflaged by surrounding density, and when overall density falls the pattern becomes apparent. The person then experiences a permanent-feeling change occurring during an effluvium episode, and attributes all of it to the effluvium. When the effluvium recovers, the pattern component does not, and they conclude the drug caused permanent loss.

How to tell them apart

The discriminating sign is miniaturisation, and it is assessed by looking at hair calibre in the affected area compared with the occipital scalp, which is spared in androgenetic alopecia. That is what a dermatologist does with a dermatoscope in about ninety seconds, and it is the reason an examination is worth more here than any amount of reading.

Why it matters practically: androgenetic alopecia has treatments with genuine randomised evidence, and they work better the earlier they start, because they preserve follicles rather than resurrecting them. Someone who spends a year assuming their pattern thinning is an effluvium that will recover has lost a year of the only intervention that would have helped. Conversely, someone with a pure effluvium who starts a long-term treatment they did not need has taken on a commitment for a condition that was going to resolve.

Two other diagnoses worth an examination rather than a forum: scarring alopecias, which are permanent and need prompt treatment, and alopecia areata, which produces discrete round patches rather than diffuse thinning. Neither is caused by this class, and both are missed when everything gets attributed to the drug.

On the supplement question, since anyone shedding hair will be sold a great many things and the evidence is worth separating from the marketing.

What has evidence

• Correcting a demonstrated deficiency. Iron in demonstrated iron deficiency, protein in demonstrated inadequacy, thyroid replacement in demonstrated hypothyroidism, zinc in demonstrated zinc deficiency. That is the entire list of nutritional interventions with a sound basis, and the operative word in each is "demonstrated".
• Minoxidil, topical or low-dose oral, has randomised evidence in androgenetic alopecia and is also used in chronic effluvium. It works while used and the benefit is lost on stopping. A clinician's decision, and low-dose oral use is off-label in most places with its own considerations.
• Antiandrogens, where appropriate to the diagnosis and the person. Genuine evidence, genuine considerations, clinician territory.
• Removing the insult. Slowing the rate of loss and fixing intake. Not a supplement, and the highest-yield intervention available.

What does not have evidence

• Biotin in people who are not biotin deficient, which is nearly everybody. No good evidence for hair growth, and a real practical harm: biotin at supplement doses interferes with streptavidin-biotin immunoassays, which include many thyroid tests, some troponin assays and some hormone panels. It has caused misdiagnosis in both directions. If you take it, tell whoever orders your bloods, and stop it for a few days beforehand.
• Collagen supplements. Hair is keratin, not collagen. Collagen is an incomplete protein, low in cysteine, which is the amino acid keratin actually needs. Eating adequate total protein does everything this is claimed to do and does it more cheaply.
• Proprietary hair vitamin blends, which are generally biotin plus a multivitamin plus something botanical, priced according to the desperation of the market rather than the evidence.
• Rosemary oil, caffeine shampoos, scalp massage, derma-rolling. Small, low-quality studies exist for some. None would change management.
• Selenium and vitamin A supplementation, which are worse than useless: excess of either causes hair loss. There is a real risk of someone shedding hair, taking a high-dose multivitamin plus a separate selenium supplement plus a hair blend, and reaching an intake that is itself a cause.

The honest summary is that the two things that will determine your outcome are the rate of loss and your protein intake, both of which are free, and that the supplement aisle exists because those two answers are unsatisfying. Nothing here is medical advice, and a demonstrated deficiency is a clinical matter rather than a shopping decision.